MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 47 Publications

10 Customer Reviews

  • MDA-MB-231 cells were treated with 10 uM MG132 and incubated under normoxia or hypoxia for 4 h. Endogenous interaction between LATS2 and SIAH2 was analysed by immunoprecipitation.

    Nat Cell Biol 2015 17(1), 95-103. MG-132 purchased from Selleck.

    HeLa cells were transfected with control mimic, RMND5A siRNA or miR-138 mimic. After transfection for 36 h, cells were treated with proteasome inhibitor MG132 (20 uM) or Dimethyl sulfoxide (DMSO) for 8 h. Endogenous Exportin-5 protein and RMND5A protein expression was measured by western blotting.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

  • HeLa cells were transfected with negative control mimic, miR-138 mimic or RMND5A siRNA. After transfection for 36 h, cells were treated with MG132 (20 uM) or DMSO for 8 h. RMND5A and Exportin-5 protein expression were analyzed by immunocytochemistry. Nuclei were counterstained with DAPI.

    Nucleic Acids Res 2014 42(1), 458-74. MG-132 purchased from Selleck.

     

    TFEB induced autophagy dependent ATZ clearance in vitro. MEF transiently co-transfected with either ATZ plus GFP expressing plasmids or ATZ plus TFEB expressing plasmids were incubated with proteasome inhibitor MG132 or with DMSO for 6 h. Upon MG132 treatment, steady state levels of 52 kDa ATZ band increased in both cells transfected with ATZ plus GFP and with ATZ plus TFEB expressing plasmids. Quantification of band intensities showed a 48% reduction of ATZ in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP, in the absence of the proteasome inhibitor. In MG132 treated cells, a 61% decrease of ATZ was detected in cells transfected with ATZ plus TFEB compared to cells transfected with ATZ plus GFP.

    EMBO Mol Med 2013 5, 397-412. MG-132 purchased from Selleck.

  • JAK1 expression was analyzed in A375 cells expressing scrambled shRNA or shRNF125 (#2) and treated with MG132 (5 uM, 10 hr), and in Lu1205 cells expressing WT RNF125 and treated with MG132.

    Cell Rep 2015 11(9), 1458-73. MG-132 purchased from Selleck.

    LRB1 and LRB2 regulate phyB protein levels. PhyB protein levels in crude extracts from the wild type (WT) and the indicated mutant backgrounds were assayed by immunoblot analysis with anti-phyB monoclonal antibodies. Anti-PBA1 and anti-histone H3 antibodies were used to confirm equal protein loading. Rc-induced loss of phyB in the wild type is inhibited by 100 uM MG132.

    Plant Physiol 2012 60(1), 118-34. MG-132 purchased from Selleck.

  • Representative images for γ-H2AX-stained cells treated with 100 uM FA for 3 h without or with MG132. Fluorescence was measured in at least 50 nuclei in each of three experiments.

    Toxicol Appl Pharmacol 2015 286(2), 135-41. MG-132 purchased from Selleck.

    GSK-3β phosphorylation at Ser9 is enhanced in NOK-overexpressed stable cell lines. The proteasome inhibitor, MG132, was added in medium of HeLa-HA and HeLa-NOK-HA cells for 12 h and then the p-GSK-3b(Ser9) was assayed by western blotting.

    FEBS Lett 2012 586, 3787–3792. MG-132 purchased from Selleck.

  • Nek2A impedes SuFu ubiquitination. HEK293T cells transfected with Nek2A-Myc and Flag-SuFu for 48 h were treated with MG-132 to enrich ubiquitinated proteins, and subsequently subjected to co-immunoprecipitation assay. Precipitated proteins were probed using anti-Ub antibody.

    Int J Oncol, 2017, 50(2):373-380. MG-132 purchased from Selleck.

    Truncated mouse Period2 (Per2) protein was expressed in NIH3T3 cells, treated by cycloheximide with or without MG132 for 1-4 hours.Per2 was reported to be degraded by the proteasome proteolysis. By adding MG132 (25 μM), a proteasome inhibitor, the degradation of Per2 was dramatically decreased within 4 hours treatment (shown by western blot).

    2012 Dr. Edison DUKE-NUS Graduate Medical School Singapore.. MG-132 purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
20S proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells MmL2SpVv[3Srb36gRZN{[Xl? NYHFPIlSOjVizszN Mn\OSG1UVw>? M1G3PGlvcGmkaYTzJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAxNjFizszN MVqyOFY6PzR7Nh?=
HL-60 M3S4XWN6fG:2b4jpZ{BCe3OjeR?= MYW0NEDPxE1? M3LR[VQ5KGh? M1;Ee2ROW09? MVTJR|UxRDFyIN88US=> MoLMNlQ3QTd2OU[=
SMMC-7721 M13sdGN6fG:2b4jpZ{BCe3OjeR?= MWi0NEDPxE1? MoroOFghcA>? MXnEUXNQ NYTxS5dVUUN3ME23MlEh|ryP MXOyOFY6PzR7Nh?=
A-549 Mn6yR5l1d3SxeHnjJGF{e2G7 MnTTOFAh|ryP MmPJOFghcA>? NU\2V|VoTE2VTx?= NH3OT|VKSzVyPEGwJO69VQ>? NXjzUoxYOjR4OUe0PVY>
MCF-7 M37v[mN6fG:2b4jpZ{BCe3OjeR?= NEf6UGw1OCEQvF2= MmGwOFghcA>? Ml\5SG1UVw>? NFj0R5hKSzVyPUeuN{DPxE1? NFzmeYozPDZ7N{S5Oi=>
SW-480 M2jXc2N6fG:2b4jpZ{BCe3OjeR?= NXfkT3p1PDBizszN MYK0PEBp NHf6[GJFVVOR NV\KNHV4UUN3ME20JO69VQ>? M{fZU|I1Pjl5NEm2
NCI-H929 NF[yc2lEgXSxdH;4bYMhSXO|YYm= Mn76NUDPxE1? NWjHbWw2PzJiaB?= M2HmUWROW09? M4XpTGlEPTB;MD6xO{DPxE1? M1LBZlI1PjJ3MEi4
293T NIj3PVhEgXSxdH;4bYMhSXO|YYm= NHfqeXIyOCEQvF2= M3vVXVczKGh? MXLEUXNQ NF;sdXVKSzVyPEKg{txO NIDwUpAzPDZ{NUC4PC=>
293T NYOyXGZ1TnWwY4Tpc44hSXO|YYm= NYLiZ2lyOTBizszN M2HPWFI1KGh? MojZSG1UVw>? Mnq1UY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? MUKyOFYzPTB6OB?=
HeLa M1rye2tqdmG|ZTDBd5NigQ>? MnjKNVAh|ryP NVzjd|NCOSCq MW\EUXNQ Ml7LTY5lfWOnczDQRXJRKGOuZXH2ZYdmKGK7IHnubIljcXSrbnegdJJwe2Wjc3;t[UBi[3Srdnn0fS=> NGT3bm0zPDN{MUizNy=>
MDA-MB-231 M1ftdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrkfYUyKM7:TR?= MofJO|IhcA>? MlnYSG1UVw>? NGL3OoVKSzVyPUCuNVgh|ryP MX6yOFE2OzJyNh?=
MCF-7 NEfTXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3FZVcyKM7:TR?= Ml\IO|IhcA>? NVzQR3NsTE2VTx?= M3i2[2lEPTB;MD6xN{DPxE1? MlTNNlQyPTN{ME[=
MCF10A MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHCNUDPxE1? MliwO|IhcA>? NUH6dnQ{TE2VTx?= NH3VXWZKSzVyPUCuNlkh|ryP NIX2fIczPDF3M{KwOi=>
HEK-293 MmqyT4lv[XOnIFHzd4F6 M{PWcFIh[W6mIEKwJO69VQ>? NUPBUIt4OiCq NIjlc5JFVVOR MWDJcohq[mm2czDDbHQuVCCjY4Tpeol1gSC5aYToJGlEPTBib3[gPUBvVSB? NXTPWplDOjN3NEC3PVA>
Calu6 MYXGeY5kfGmxbjDBd5NigQ>? NF:y[28yOCEQvF2= NXHqSFJWOThiaB?= MWPEUXNQ NHvieGRUcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=> MXqyN|UxPjR6Nh?=
IFN-gamma-induced RAW264.7 NFrNXIFHfW6ldHnvckBCe3OjeR?= MWPEUXNQ NVGwXHp5UW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>? M3KwXVIzOjd5Mke3
IPC227F MVHDfZRwfG:6aXOgRZN{[Xl? M4L5NFEh|ryP MVy0PEBp NGXmcGlFVVOR M1LqV2lEPTB;MD6wO|ch|ryP MVSyNVkzPDV{OB?=
Hepa-1c1c7 M2G1e2Z2dmO2aX;uJGF{e2G7 MX6yOUDPxE1? M363dFYhcA>? M3XnemROW09? MXTJcoNz\WG|ZYOgUpJnOiCycn;0[YlvKGyndnXs MVGyNFM6OjV2NB?=
COS-7 NV;3emprS3m2b4TvfIlkKEG|c3H5 NYH5UXVxOTBizszN MYDEUXNQ MYPJR|UxRDFyIN88US=> M2DBT|E5ODh6MEm3
HuH-7 NX;qOVBFS3m2b4TvfIlkKEG|c3H5 NYHySoh[OTBizszN MljKSG1UVw>? M4nzd2lEPTB:MUCg{txO M4LRNlE5ODh6MEm3
OCI-Ly3 NYX1Z2xyTnWwY4Tpc44hSXO|YYm= NVPob3BEOTBizszNxsA> MV:0JIg> MkjSSG1UVw>? NGf1b4xKdmS3Y3XzJIh2dWGwIFnrZZBx[UKjbIDoZUB{fGGkaXzpfoF1cW:wIIfpeIghTUN3MDDv[kAyKM7:TR?= M{nZR|E5ODJ2MUGz
A2780 cDDP M4foNWFxd3C2b4Ppd{BCe3OjeR?= NILSZo4zPCCq NIjGU2JFVVOR M3zmR2lv\HWlZYOgZZBweHSxc3nzJIJ6KGmwaHnibZRqdmdiUGTFUkBl\We{YXTheIlwdg>? NFe5WYQyPzZ6NECxPC=>
LPS-stimulated RAW264.7 cells MlezSpVv[3Srb36gRZN{[Xl? NVrvbJU1TE2VTx?= MmPxTY5pcWKrdIOgUmYuc2GycHHCJGRPSSCkaX7kbY5o NITGPG0yPzRyN{K3Oy=>
PC12 NUS1WmpSTnWwY4Tpc44hSXO|YYm= Ml3CNVAxKM7:TdMg NHLGTmQzPCCq M4DIVmROW09? M3TmPGlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk> MWmxO|E2QDR3NB?=
PC3 M4DITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[yNEDPxE1? MYK0PEBp NXvlSIdNTE2VTx?= MmrmTWM2OD1yLk[g{txO MkPVNVY3QDZ3M{e=
LP-1 M1jiS2Fxd3C2b4Ppd{BCe3OjeR?= NHnYZ2Q{ODBibl2= NIHITngzPCCq M4[y[GROW09? NXXDRotNUW6mdXPld{BieG:ydH;zbZMh[nliaX7jdoVie2mwZzDjcIVifmWmIGDBVnAhdGW4ZXygZY5lKHKnZIXjbY5oKE2lbD2xJJBzd3SnaX6gcIV3\Wx? MkjhNVU6PTh3OEm=
ES6 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEGzNFYh|ryP M3fGbHNCVkeHUh?=
A101D NF\DRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknLTWM2OD1yLkCzNlc6KM7:TR?= MnPsV2FPT0WU
OCUB-M M1HQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Lrb2lEPTB;MD6wN|c{PyEQvF2= NIjmbldUSU6JRWK=
LB2518-MEL NXzqNHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L6dGlEPTB;MD6wN|c3KM7:TR?= M1Pne3NCVkeHUh?=
SH-4 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXqTWM2OD1yLkC0N|Eh|ryP MXTTRW5ITVJ?
KNS-42 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTy[VBiUUN3ME2wMlA1PDRzIN88US=> NUCyTpJoW0GQR1XS
DSH1 M4SwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jHTGlEPTB;MD6wOVI5QSEQvF2= MV7TRW5ITVJ?
NTERA-S-cl-D1 NYqxO3JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHVb3Q6UUN3ME2wMlA2Pzd{IN88US=> NGTk[FdUSU6JRWK=
D-542MG MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7JTWM2OD1yLkC1PVU4KM7:TR?= MXPTRW5ITVJ?
KS-1 M{m4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfuTWM2OD1yLkC2OFU5KM7:TR?= NFz4VGhUSU6JRWK=
BL-41 NIHIZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjqdFhKSzVyPUCuNFY6PDdizszN NGOzcFJUSU6JRWK=
LXF-289 M4\oS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEewOlYh|ryP M3\tTHNCVkeHUh?=
D-247MG MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDZTWM2OD1yLkC3NlA6KM7:TR?= NY\MSnZiW0GQR1XS
MMAC-SF NIfscXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEeyOlgh|ryP M{X3TXNCVkeHUh?=
CP66-MEL NHLMTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEe1JO69VQ>? M4HvW3NCVkeHUh?=
LB771-HNC Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fOZ2lEPTB;MD6wPFA{PiEQvF2= NU\PT2ZmW0GQR1XS
no-10 NEj0R49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEi5NFkh|ryP M2jiOHNCVkeHUh?=
A388 NFLyOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO4PXhoUUN3ME2wMlA6ODZ3IN88US=> M{XOR3NCVkeHUh?=
OPM-2 NIfyc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMUC0O|Qh|ryP NXu3bG9sW0GQR1XS
OVCAR-4 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nqO2lEPTB;MD6xNFk{QCEQvF2= M3nUSXNCVkeHUh?=
HOP-62 NVrHXVU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLzOoRKSzVyPUCuNVA6PDlizszN NIezWZFUSU6JRWK=
ML-2 NH7CXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\uVWlwUUN3ME2wMlEyQDB4IN88US=> NEW3WFNUSU6JRWK=
UACC-257 NGfxfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr2TWM2OD1yLkGxPVI4KM7:TR?= MX;TRW5ITVJ?
NEC8 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUG5PVUh|ryP MYrTRW5ITVJ?
ONS-76 NVq5ZpNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fSSGlEPTB;MD6xNlk{PSEQvF2= M4jHbXNCVkeHUh?=
KE-37 MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;IdpVKSzVyPUCuNVMzPzhizszN NYfOR3BbW0GQR1XS
HT-144 NYrSWYlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMUO4PVUh|ryP MWLTRW5ITVJ?
LB2241-RCC MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;CdZliUUN3ME2wMlE1OjR5IN88US=> M{\RZ3NCVkeHUh?=
TE-5 M4P2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjFSmpsUUN3ME2wMlE1Ojd6IN88US=> NVvqTZd6W0GQR1XS
KINGS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHVTWM2OD1yLkG0O|kh|ryP M3\hb3NCVkeHUh?=
NCI-H69 M4fifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zibmlEPTB;MD6xOVE1OSEQvF2= M36wNHNCVkeHUh?=
CAS-1 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEKwPIdKSzVyPUCuNVU1QDJizszN MVHTRW5ITVJ?
D-263MG MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HvbWlEPTB;MD6xOlAxPiEQvF2= NVT1bJZSW0GQR1XS
A253 NUDacFlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMU[xNlgh|ryP NIfjXI1USU6JRWK=
PF-382 NID5b2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DX[WlEPTB;MD6xOlcxPiEQvF2= MoPiV2FPT0WU
CESS M2rvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfWS5dKSzVyPUCuNVcxPiEQvF2= NHLrbXNUSU6JRWK=
MZ2-MEL NGjhVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjNTWM2OD1yLkG3OVU6KM7:TR?= MlLvV2FPT0WU
HEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3VTWM2OD1yLkG4OVE4KM7:TR?= NGruVYRUSU6JRWK=
D-392MG NYGyS2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q1bmlEPTB;MD6xPVEyPSEQvF2= NUjNcGJTW0GQR1XS
SK-LMS-1 NWnJTox7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rnSmlEPTB;MD6xPVMxOyEQvF2= Mk\BV2FPT0WU
GI-ME-N NVqydIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW2NopKSzVyPUCuNVk{ODZizszN NG\D[5FUSU6JRWK=
LB831-BLC NF3HOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzGTWM2OD1yLkG5N|Qh|ryP MoCyV2FPT0WU
DU-4475 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r2b2lEPTB;MD6xPVY2QCEQvF2= MUHTRW5ITVJ?
IST-SL1 NUnXTZEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMkCwPVQh|ryP MlXTV2FPT0WU
GAK Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMkC1N|Qh|ryP NEHNdoJUSU6JRWK=
EW-1 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH2VYZKSzVyPUCuNlExPDdizszN NWDrVI1OW0GQR1XS
LAMA-84 NE\IZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LwWmlEPTB;MD6yNVg2OSEQvF2= NVjufo5KW0GQR1XS
SK-UT-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMkKwOFkh|ryP MlK2V2FPT0WU
VA-ES-BJ MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHWVIVXUUN3ME2wMlIzOjV5IN88US=> Ml;BV2FPT0WU
ACN M1\OOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDXS|lLUUN3ME2wMlIzPjN6IN88US=> MX\TRW5ITVJ?
SK-PN-DW NIHPfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjSTWM2OD1yLkKzNVkh|ryP NFrld2RUSU6JRWK=
HD-MY-Z MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWwWFc2UUN3ME2wMlI{OzB|IN88US=> NEnUfodUSU6JRWK=
LB373-MEL-D NYLRXpg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XKb2lEPTB;MD6yOFE6QCEQvF2= M3v5[nNCVkeHUh?=
COLO-829 NFS3[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXmTWM2OD1yLkK0NlU4KM7:TR?= NWDnVFhLW0GQR1XS
ES8 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\HTWM2OD1yLkK0O|Y{KM7:TR?= NWLD[WhpW0GQR1XS
RXF393 NGDLO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWP0bHI5UUN3ME2wMlI2ODF3IN88US=> MXvTRW5ITVJ?
TK10 M2DyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDhZ2s1UUN3ME2wMlI2PDN3IN88US=> M{HEdnNCVkeHUh?=
LOUCY NETUT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjjb3BKSzVyPUCuNlU1PTZizszN MmjrV2FPT0WU
MZ7-mel MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rDVWlEPTB;MD6yOlM4PCEQvF2= MYLTRW5ITVJ?
CP67-MEL NYHGbZc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HKcGlEPTB;MD6yOlc{KM7:TR?= MmP4V2FPT0WU
C2BBe1 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HuO2lEPTB;MD6yO|kxPyEQvF2= MmfSV2FPT0WU
K052 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n5fmlEPTB;MD6yPFk6KM7:TR?= M4XnNHNCVkeHUh?=
MOLT-16 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjs[5lKSzVyPUCuNlk2OjRizszN NUP3Z4ttW0GQR1XS
KNS-81-FD NYLvcph1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37ocGlEPTB;MD6zNFMzOyEQvF2= MmX1V2FPT0WU
CMK MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDjSJZtUUN3ME2wMlMyOTJizszN MmLqV2FPT0WU
LAN-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrzOZQ3UUN3ME2wMlMyOyEQvF2= M1XyXHNCVkeHUh?=
KLE MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPkXGFtUUN3ME2wMlMyOzB4IN88US=> MoDCV2FPT0WU
NCCIT MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzaVnRPUUN3ME2wMlMyPzh|IN88US=> MV\TRW5ITVJ?
HH MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi3TWM2OD1yLkOyPFk4KM7:TR?= NUCxd|dXW0GQR1XS
TE-8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M370XmlEPTB;MD6zOFI4QSEQvF2= Mly4V2FPT0WU
GDM-1 NUTPRlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rVeGlEPTB;MD6zOVExPCEQvF2= M2jIeHNCVkeHUh?=
NCI-H747 NYG2fW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTiTWM2OD1yLkO3NVA{KM7:TR?= NHnOUmxUSU6JRWK=
NCI-H1092 NVW2WXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwM{i4OFQh|ryP MoLlV2FPT0WU
8-MG-BA MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HBSmlEPTB;MD6zPVg{PyEQvF2= M17HUXNCVkeHUh?=
NB17 NXf2W3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXnc3RuUUN3ME2wMlQzQTdizszN NU\zbGJmW0GQR1XS
LC4-1 NXXpV|FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi5UI5oUUN3ME2wMlQ{PjB5IN88US=> MlXoV2FPT0WU
TE-1 NUPLWYRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwNEWxNVkh|ryP MVnTRW5ITVJ?
KALS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\VS2lEPTB;MD60OlU5PCEQvF2= M{PENnNCVkeHUh?=
CCRF-CEM MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr0cIdKSzVyPUCuOFc3PzRizszN MYDTRW5ITVJ?
OS-RC-2 M{Pte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fiRWlEPTB;MD60O|k4OiEQvF2= M2n3dnNCVkeHUh?=
A704 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILkWWRKSzVyPUCuOFg3QTJizszN MoDHV2FPT0WU
BB49-HNC M1fDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwNEmwPVYh|ryP MofwV2FPT0WU
EVSA-T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoCzTWM2OD1yLkS5PVEyKM7:TR?= NIfOXpJUSU6JRWK=
Mo-T NUTzbm94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLjcVRKSzVyPUCuOVE4PjJizszN MXLTRW5ITVJ?
MONO-MAC-6 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XoNWlEPTB;MD61N|YyOSEQvF2= MmPuV2FPT0WU
BB65-RCC MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnITWM2OD1yLkW2PFEyKM7:TR?= M1HlUXNCVkeHUh?=
NCI-H1882 NFjYZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwNUmwN|Yh|ryP M323ZnNCVkeHUh?=
TE-9 NUHBNY1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTS[npYUUN3ME2wMlYyODN|IN88US=> MmPOV2FPT0WU
NCI-H2126 NWmz[Zc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNkK2Olkh|ryP Mo\4V2FPT0WU
SF268 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXWeGpKSzVyPUCuOlU3PDFizszN MoPJV2FPT0WU
SW872 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTlfoF6UUN3ME2wMlY2PzJ7IN88US=> M{K0fHNCVkeHUh?=
LS-513 M3fNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXizc4JGUUN3ME2wMlY3PzVzIN88US=> Mnf1V2FPT0WU
NCI-H1355 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jZVGlEPTB;MD62PFYyQSEQvF2= MUfTRW5ITVJ?
BL-70 NGD2WGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;MV5czUUN3ME2wMlY6Ozh6IN88US=> MXTTRW5ITVJ?
NCI-SNU-5 M2jMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEO4OZhKSzVyPUCuOlk2PDVizszN NELYUWlUSU6JRWK=
SNU-C2B NFvOWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHkTWM2OD1yLkewO|M6KM7:TR?= NHrZbHJUSU6JRWK=
GB-1 NYLKRo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHLPJlNUUN3ME2wMlczOTJ2IN88US=> M{HucnNCVkeHUh?=
CTB-1 NU\lWVFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Lh[2lEPTB;MD63O|k2PSEQvF2= NInBOmpUSU6JRWK=
Becker Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37Y[mlEPTB;MD63PVYzOSEQvF2= MoDwV2FPT0WU
KM12 MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vKOGlEPTB;MD64OVQ3PiEQvF2= MV3TRW5ITVJ?
ES7 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fsbWlEPTB;MD64PVY2KM7:TR?= M3fXdXNCVkeHUh?=
COLO-684 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2e4ZWlEPTB;MD65NFY2QCEQvF2= M4LsPHNCVkeHUh?=
HCC2998 M4TtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;m[45wUUN3ME2wMlk{QDV2IN88US=> M4fMOXNCVkeHUh?=
TE-10 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwOU[0N{DPxE1? NIO4dmxUSU6JRWK=
SF126 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HnbWlEPTB;MD65PFk4OSEQvF2= MkmxV2FPT0WU
EKVX NInSbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnrS3R5UUN3ME2xMlA{PDR{IN88US=> MV\TRW5ITVJ?
KARPAS-45 M1TpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlznTWM2OD1zLkC0NFE3KM7:TR?= MWfTRW5ITVJ?
KGN NELhcFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPhTWM2OD1zLkC1NFQ2KM7:TR?= NI\USXBUSU6JRWK=
ES1 M1r5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMEe5NlEh|ryP M3nxRXNCVkeHUh?=
L-540 M1r1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwMUG4N|kh|ryP M1;OXHNCVkeHUh?=
KURAMOCHI M4XOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHVeFdKSzVyPUGuNVI{PzRizszN MnjwV2FPT0WU
LU-65 NV\CO3k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PUS2lEPTB;MT6xNlc2OyEQvF2= M2\kSnNCVkeHUh?=
MFH-ino M3u4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL1blVKSzVyPUGuNVc2ODFizszN NXfHUoM1W0GQR1XS
NCI-H23 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwMkC0NUDPxE1? NX;2dmtXW0GQR1XS
IA-LM MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwMkSxNVYh|ryP M2XSfHNCVkeHUh?=
PSN1 NWHRfYx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PL[GlEPTB;MT6yO|AyPiEQvF2= NF7yb3dUSU6JRWK=
NCI-H719 M4XW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3STWM2OD1zLkK3OFEyKM7:TR?= M{H1ZnNCVkeHUh?=
SW684 NWn2OXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pkb2lEPTB;MT6yPFY2QSEQvF2= M3n2Z3NCVkeHUh?=
HCE-4 NGPl[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K0RWlEPTB;MT6zNFIzOSEQvF2= NHvTWGZUSU6JRWK=
EW-16 M3PtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwM{GzOFch|ryP NF;xb4pUSU6JRWK=
NCI-H128 NHT4XJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKxXGxoUUN3ME2xMlM2QDF2IN88US=> M2G1RXNCVkeHUh?=
HC-1 NEjrSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\DcXNKSzVyPUGuN|gyPyEQvF2= MXXTRW5ITVJ?
IST-MES1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHzTWM2OD1zLkSwNlA5KM7:TR?= M4fzZXNCVkeHUh?=
Raji NV;RNWdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwNEG4OUDPxE1? MXHTRW5ITVJ?
DMS-114 M2rKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2frc2lEPTB;MT60OFU{QSEQvF2= M1;SZXNCVkeHUh?=
GI-1 Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPGflF3UUN3ME2xMlQ4OTNzIN88US=> Ml;WV2FPT0WU
NCI-H2081 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\1eWlEPTB;MT61OVE6PiEQvF2= NUKyT4liW0GQR1XS
LC-1F NI\kT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwNUWxPVgh|ryP NHG2Z|FUSU6JRWK=
NCI-H2227 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHVRVhKSzVyPUGuOlE2PjFizszN M2n1TXNCVkeHUh?=
D-502MG MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jpc2lEPTB;MT62O|IyOSEQvF2= NFywdotUSU6JRWK=
NCI-H2141 NVTTbo5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojDTWM2OD1zLk[3N|E4KM7:TR?= MXzTRW5ITVJ?
LS-411N NVuz[3htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jzRWlEPTB;MT62PVgxPyEQvF2= MkXEV2FPT0WU
SU-DHL-1 NWjuU|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;OS5RKSzVyPUGuO|EzQDFizszN NXznRWFKW0GQR1XS
BB30-HNC NFvTNJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfjTWM2OD1zLkeyOlg2KM7:TR?= NXL0SoR[W0GQR1XS
TE-15 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITxPFJKSzVyPUGuPVI{PzNizszN NUH1RoVDW0GQR1XS
JVM-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;HTGlEPTB;MT65N|kxPCEQvF2= NGjCZXpUSU6JRWK=
IST-SL2 M3OwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn4fXhuUUN3ME2yMlAyOjV{IN88US=> MlnLV2FPT0WU
EW-18 M3q3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwMEKzN|ch|ryP Mki2V2FPT0WU
DJM-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXTSIg6UUN3ME2yMlAzPTV{IN88US=> MUfTRW5ITVJ?
no-11 M4rsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnNTWM2OD1{LkCzNVA1KM7:TR?= M1HVdHNCVkeHUh?=
QIMR-WIL NYPwNIN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4POXWlEPTB;Mj6xOlc3OiEQvF2= MUfTRW5ITVJ?
MC-CAR NIK4T|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj6XGxKSzVyPUKuNlI6PSEQvF2= NUjPSFV5W0GQR1XS
KM-H2 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTRW3hKSzVyPUKuNlkxPDNizszN NXm1PGtWW0GQR1XS
ECC12 NHvOboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETqWJBKSzVyPUKuN|c6PCEQvF2= M4HBNXNCVkeHUh?=
HCE-T NYSyZXp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjjd3NKSzVyPUKuOFQ5QDNizszN NXu0SZdoW0GQR1XS
MFM-223 NIjze5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3fWlEPTB;Mj61NFg4OSEQvF2= NGHNeo5USU6JRWK=
SW982 NVn2TYpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrRfHZjUUN3ME2yMlUyPDhizszN NIrWWJZUSU6JRWK=
KG-1 NF7yVVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\j[5ppUUN3ME2yMlg5PzlzIN88US=> MVnTRW5ITVJ?
ES4 M4XoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojTTWM2OD1|LkC2NVEyKM7:TR?= MlLXV2FPT0WU
SCC-3 NUjENm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT3TWM2OD1|LkGwPFQ5KM7:TR?= M3vxe3NCVkeHUh?=
RH-1 NEDWUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTNwM{i3OFgh|ryP MVjTRW5ITVJ?
NCI-H748 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwNESyOlYh|ryP MVzTRW5ITVJ?
HCC2218 M4nl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHzXVVXUUN3ME2zMlQ3QTN5IN88US=> NWS2THd3W0GQR1XS
MEG-01 NEK0dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwNUm2PEDPxE1? NHjqZoxUSU6JRWK=
NB12 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\heoVKSzVyPUOuOVk5QDhizszN M3HCZXNCVkeHUh?=
SNB75 NYDJUllWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3TTWM2OD1|Lk[wNVA{KM7:TR?= M{[xOnNCVkeHUh?=
KMS-12-PE MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7zTWM2OD1|Lk[3O|I{KM7:TR?= NImwTI9USU6JRWK=
SKM-1 M4XuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H1cGlEPTB;Mz63NVM4PiEQvF2= NGG3eIdUSU6JRWK=
COLO-320-HSR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X5eGlEPTB;Mz63OVY{PCEQvF2= MUjTRW5ITVJ?
NKM-1 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXvPHdKSzVyPUOuO|c{PzhizszN NIO1bXlUSU6JRWK=
TE-6 NWeyboNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfETWM2OD1|Lkm0OVYyKM7:TR?= MXXTRW5ITVJ?
D-336MG NYrKZohzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy3ZWtKSzVyPUSuNFEyPjZizszN M{G4XXNCVkeHUh?=
NCI-H1650 M33HXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\teG9KSzVyPUSuNVU4QTdizszN NUDSdpF2W0GQR1XS
ES3 M4nlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP5SHlNUUN3ME20MlMzQDJ2IN88US=> NY\hVYUyW0GQR1XS
YT NVXxS|NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D5UWlEPTB;ND6zOVQzPCEQvF2= M2LSbnNCVkeHUh?=
ES5 M1n1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPiTWM2OD12LkSwNlU2KM7:TR?= NFH6WoJUSU6JRWK=
LB647-SCLC MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTRwNU[zNFgh|ryP NFyyN2JUSU6JRWK=
HAL-01 Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwNUewN|Qh|ryP NVfESJZuW0GQR1XS
LP-1 NY\TSFJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr1ZoVKSzVyPUSuO|I{PzFizszN NW\3UYlDW0GQR1XS
BC-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHywVnVKSzVyPUWuNFA1PDdizszN NYfMV4tKW0GQR1XS
EB-3 MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVwMEOwOFEh|ryP Mnr0V2FPT0WU
GT3TKB Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;yWZJrUUN3ME21MlE4PjZ{IN88US=> MUPTRW5ITVJ?
NCI-H209 NWPkdmZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LVe2lEPTB;NT6xPVM2OiEQvF2= MlexV2FPT0WU
BT-474 NELqXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv4RY8{UUN3ME21MlI{OTB{IN88US=> NVqyOZJEW0GQR1XS
RKO MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTVwMkO0NlIh|ryP NFLQTWJUSU6JRWK=
SIMA NU\aVpR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3WRmtVUUN3ME21MlMxPzZ3IN88US=> MmOzV2FPT0WU
RL M3HXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjsXWpKSzVyPUWuN|c2PDFizszN NGXQPHFUSU6JRWK=
GCIY MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnITWM2OD13LkS3NlM3KM7:TR?= MXrTRW5ITVJ?
Calu-6 NX7Nc3pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK4XZFbUUN3ME21MlYzOiEQvF2= NWfNWXNKW0GQR1XS
ALL-PO NV\5UGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDRWYg6UUN3ME21MlY{Pzl3IN88US=> NUXOV3hWW0GQR1XS
ARH-77 NG\mPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLtVnV3UUN3ME21MlY4ODh5IN88US=> NHPIeGhUSU6JRWK=
A4-Fuk MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;5TWlKSzVyPU[uNFgyOThizszN NXjuW4toW0GQR1XS
NCI-H1581 M2L1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n5XGlEPTB;Nj6yN|g1QSEQvF2= M{XRWnNCVkeHUh?=
HUTU-80 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LjNmlEPTB;Nj6zOlg6PyEQvF2= Mnz6V2FPT0WU
TGW NEP3NopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHYTWM2OD14LkS1OVk{KM7:TR?= MXzTRW5ITVJ?
SK-N-FI M4PUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LXPWlEPTB;Nj60OVg2PCEQvF2= Mn:3V2FPT0WU
U-266 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\3TWM2OD14LkWxPVI3KM7:TR?= NFH0WZVUSU6JRWK=
EM-2 M2K3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTZwNkewPVkh|ryP MUDTRW5ITVJ?
NMC-G1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojSTWM2OD14LkexPFk2KM7:TR?= MVTTRW5ITVJ?
KASUMI-1 M1PKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LRfGlEPTB;Nj64OFc5PyEQvF2= NX3PNFRKW0GQR1XS
NALM-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTMem1YUUN3ME22Mlg3PzV2IN88US=> MYDTRW5ITVJ?
OCI-AML2 M1nVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXqTWM2OD15LkCwN|I3KM7:TR?= NXLUPXhjW0GQR1XS
SHP-77 M4XYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\pWIR6UUN3ME23MlIzPDNizszN MmHFV2FPT0WU
NOMO-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M331S2lEPTB;Nz6yOFI2PCEQvF2= MmTnV2FPT0WU
SK-N-DZ NHH0empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTdwN{GwPFkh|ryP MnvhV2FPT0WU
LB1047-RCC M33iZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ywN2lEPTB;Nz63NlI{OSEQvF2= M{\XSnNCVkeHUh?=
MZ1-PC MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC5TWM2OD15Lki2OVU5KM7:TR?= M{LEW3NCVkeHUh?=
NB10 M3vSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHvU4xKSzVyPUeuPVk2PTZizszN MWrTRW5ITVJ?
RL95-2 M{Sye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRThwMUC4OFIh|ryP MmfsV2FPT0WU
OMC-1 M4HrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXqTWM2OD16LkWyNVkyKM7:TR?= MmXLV2FPT0WU
D-283MED M1fGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjWdHhKSzVyPUiuPVE4OTlizszN MVfTRW5ITVJ?
MC116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\MVoJuUUN3ME24Mlk4QTRizszN NYS3bJJ1W0GQR1XS
SJSA-1 M3LUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\GOnpKSzVyPUmuNFkxQTFizszN NWPNNppvW0GQR1XS
JiyoyeP-2003 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXibFV4UUN3ME25MlI6OzF5IN88US=> MkP2V2FPT0WU
IST-MEL1 NFjDUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDI[WlKSzVyPUmuO|QyQThizszN MlHVV2FPT0WU
CTV-1 NHrhOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnaTWM2OD1zMD6wPVc6KM7:TR?= MV3TRW5ITVJ?
NH-12 NGDLPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjBXnZUUUN3ME2xNE4zPDN|IN88US=> NX\2TVhxW0GQR1XS
CA46 NX3tZZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfDbJVKSzVyPUGwMlM3OSEQvF2= M4LKSnNCVkeHUh?=
NCI-SNU-1 NXLlO2JlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X4XWlEPTB;MUCuOFk3QSEQvF2= NUftdIp4W0GQR1XS
SCLC-21H NX3kZ5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLYTWM2OD1zMD62OVk3KM7:TR?= MofKV2FPT0WU
EC-GI-10 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzTTWM2OD1zMD63NFMyKM7:TR?= Ml\3V2FPT0WU
SR NX;F[3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDNTJM3UUN3ME2xNU4xOTh3IN88US=> NGW3SJlUSU6JRWK=
NCI-H1648 NVO1ZoFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjwPFhKSzVyPUGxMlA6PjVizszN M{i4bHNCVkeHUh?=
TGBC1TKB MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeySZlKSzVyPUGxMlQyODJizszN MYnTRW5ITVJ?
EW-11 NYm4OIJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT6Z3NKSzVyPUGxMlUyQDZizszN NGrPSWZUSU6JRWK=
SK-MM-2 NVjIXWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HoR2lEPTB;MUGuPFA3OSEQvF2= MYDTRW5ITVJ?
NCI-H524 NY\jU2FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHy[5RpUUN3ME2xNU46QDJ{IN88US=> MmDRV2FPT0WU
NOS-1 NU[0Z2tTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4m1SGlEPTB;MUKuNFM1PSEQvF2= M131eXNCVkeHUh?=
AM-38 NHSwOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDHS3pKSzVyPUGyMlU3OzNizszN NWnPT5J1W0GQR1XS
A498 M4DrbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOzTWM2OD1zMj63NFY6KM7:TR?= NEjmb4tUSU6JRWK=
KARPAS-422 NGHI[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrwZWp4UUN3ME2xNk44PDl4IN88US=> NW\hT5JmW0GQR1XS
LU-139 NVnsNoFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DQN2lEPTB;MUKuPVAzPiEQvF2= MXrTRW5ITVJ?
COR-L88 MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHwTWM2OD1zMj65N|gzKM7:TR?= NH\mfZFUSU6JRWK=
K5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnqTWM2OD1zMj65OFYzKM7:TR?= MXrTRW5ITVJ?
NB13 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;sOHlKSzVyPUGyMlk4QDNizszN NHvue4hUSU6JRWK=
MRK-nu-1 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[0ZWFKSzVyPUGzMlE6PSEQvF2= NVPMUpJiW0GQR1XS
MHH-NB-11 Ml7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHJTnNKSzVyPUGzMlI6ODJizszN M2TjTXNCVkeHUh?=
KU812 NVPzem5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPP[VhKSzVyPUGzMlYyOjRizszN NWfGTpZvW0GQR1XS
TE-12 M2LpbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\4TWM2OD1zMz62PVk1KM7:TR?= MmP1V2FPT0WU
NCI-N87 M{TYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PhT2lEPTB;MUOuO|M3KM7:TR?= NIjLUnFUSU6JRWK=
EB2 M3vieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PQfGlEPTB;MUOuPFUxPSEQvF2= MV3TRW5ITVJ?
DB MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCTWM2OD1zMz65PFg2KM7:TR?= NGjuZo5USU6JRWK=
697 NUPOVYhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF2LkS1NVEh|ryP NITZUJhUSU6JRWK=
MSTO-211H MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\5RVNKSzVyPUG0Mlc1PDhizszN MWTTRW5ITVJ?
JVM-2 NHPaW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnUTWM2OD1zND63O|M2KM7:TR?= MWjTRW5ITVJ?
COLO-824 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7zb5hKSzVyPUG0Mlc6QTRizszN Moj2V2FPT0WU
BC-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrENG53UUN3ME2xOU4{QThizszN Mni0V2FPT0WU
BOKU NWrmSpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r4bGlEPTB;MUWuPVYxQCEQvF2= MXzTRW5ITVJ?
GOTO NV3x[ItoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF4Lkm2NVch|ryP NXjER|NxW0GQR1XS
HCC2157 M2W5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOwRoNKSzVyPUG3MlQ4PTVizszN MnzQV2FPT0WU
LS-1034 M4P1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYqz[WFmUUN3ME2xO{43QDF6IN88US=> Mo\2V2FPT0WU
CAL-148 NEHP[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvqSotKSzVyPUG3Mlk4QTZizszN Mn;nV2FPT0WU
MOLT-4 MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rQV2lEPTB;MUiuPFIxQCEQvF2= MoeyV2FPT0WU
Daudi MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXlTWM2OD1zOD65NlMyKM7:TR?= MnewV2FPT0WU
J-RT3-T3-5 NX3jZ5h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz4TWM2OD1zOT60NFY3KM7:TR?= NETrPWlUSU6JRWK=
KMOE-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTCPZdIUUN3ME2xPU43PDh{IN88US=> MW\TRW5ITVJ?
HL-60 NYjiOIV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELNb|BKSzVyPUKwMlE6PjVizszN MkT6V2FPT0WU
P31-FUJ MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTzTWM2OD1{MD60O|U{KM7:TR?= M1HFS3NCVkeHUh?=
IM-9 NWTpcmZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW1TWM2OD1{MD62NlI1KM7:TR?= NFqzcZJUSU6JRWK=
HDLM-2 NGSyfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iwTmlEPTB;MkCuPFgzOSEQvF2= NVXsOlBPW0GQR1XS
NCI-H1304 M1TDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\BXWlEPTB;MkGuNFMyOSEQvF2= MX;TRW5ITVJ?
NCI-H345 M{HGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPpV3hKSzVyPUKxMlA3PDNizszN NUfzTIJ{W0GQR1XS
RPMI-6666 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\hTWM2OD1{MT6zOlAzKM7:TR?= MWPTRW5ITVJ?
GR-ST NV25bGJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L3OGlEPTB;MkGuOFE4KM7:TR?= NWriWGFWW0GQR1XS
CHP-126 M2XpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXTXZRKSzVyPUKxMlYyQDFizszN MYLTRW5ITVJ?
EHEB NGmwXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfoWJg6UUN3ME2yNU43PzNzIN88US=> MVLTRW5ITVJ?
CPC-N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ2LkCyNFEh|ryP M{H3bHNCVkeHUh?=
NB1 NGfONFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO1OHh5UUN3ME2yOE43QTN7IN88US=> M{H4OHNCVkeHUh?=
LS-123 NUP4XpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknMTWM2OD1{ND65NFEzKM7:TR?= MlPJV2FPT0WU
ST486 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLYTWM2OD1{NT6xNVE{KM7:TR?= Ml7rV2FPT0WU
NCI-H1963 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljJTWM2OD1{Nj6wOlI{KM7:TR?= NFuxNGFUSU6JRWK=
U-87-MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{THNGlEPTB;Mk[uO|Y1PCEQvF2= M3vWT3NCVkeHUh?=
COR-L279 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ4Lke5NlIh|ryP NHrjOmxUSU6JRWK=
LU-165 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr6TWM2OD1{OD6wPFYyKM7:TR?= MkC0V2FPT0WU
COLO-800 NIXkNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfXTWRKSzVyPUK4MlI6PTZizszN NX\lTZdoW0GQR1XS
ETK-1 MoHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULwOGJlUUN3ME2yPE4{PDR4IN88US=> MnrnV2FPT0WU
LNCaP-Clone-FGC NGPmTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX4TWM2OD1{OT65NlgyKM7:TR?= NH73NJZUSU6JRWK=
SIG-M5 NEXoeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vB[mlEPTB;M{CuO|k2OiEQvF2= Ml3nV2FPT0WU
NB6 NFL0e4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37QeWlEPTB;M{CuPVUxOyEQvF2= NGC1ZnJUSU6JRWK=
NCI-H2107 NISzToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yzcGlEPTB;M{GuNlM{QCEQvF2= M{LHNXNCVkeHUh?=
SNU-C1 NGjJWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnINpdjUUN3ME2zNU4{OTJ4IN88US=> MoW4V2FPT0WU
JAR Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzafYpSUUN3ME2zNU4{Pzl7IN88US=> Mkm1V2FPT0WU
L-363 NUjxRY9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2THT2lEPTB;M{KuNlE1PCEQvF2= MVzTRW5ITVJ?
EW-24 M1vqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN{LkO0O|Qh|ryP M{fpOXNCVkeHUh?=
NB69 M4HpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XOZ2lEPTB;M{OuOlQ2PCEQvF2= MXfTRW5ITVJ?
EW-13 MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTN|Lki5Olkh|ryP MmnhV2FPT0WU
Ramos-2G6-4C10 M1nhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDE[ZhiUUN3ME2zOE4zQTl|IN88US=> M2TVZXNCVkeHUh?=
TE-11 M4rjW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\6TWM2OD1|ND60PFIzKM7:TR?= MWLTRW5ITVJ?
L-428 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnviTWM2OD1|ND63OVM3KM7:TR?= MXfTRW5ITVJ?
KP-N-YN MkDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTMTWM2OD1|ND65NFU4KM7:TR?= NHTQNoRUSU6JRWK=
CGTH-W-1 NGLQVWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHtUIVKSzVyPUO2MlkxPDhizszN NWXjSIptW0GQR1XS
K-562 M{i2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN5LkC4OlQh|ryP NYfoN3JnW0GQR1XS
NCI-H1299 NFPmS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHJd3dKSzVyPUO4MlE3ODNizszN M3v2fXNCVkeHUh?=
RCC10RGB NHLQWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4izXWlEPTB;M{iuNlA5OyEQvF2= MXnTRW5ITVJ?
NCI-SNU-16 NETTSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfzT2RoUUN3ME2zPE42PjV|IN88US=> M1q1bHNCVkeHUh?=
LC-2-ad NIfW[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjjfIFKUUN3ME2zPU41OzN5IN88US=> MnLOV2FPT0WU
MHH-PREB-1 NWXFRYdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvnTWM2OD1|OT63N|g5KM7:TR?= NVG5dYNiW0GQR1XS
NCI-H64 NE[zTppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\RcmlEPTB;NECuNFk1QCEQvF2= M3\EOHNCVkeHUh?=
LB996-RCC M2n5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjxWm9mUUN3ME20NE45PzF4IN88US=> MWLTRW5ITVJ?
DEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\JfJpbUUN3ME20NU41PDB3IN88US=> MXLTRW5ITVJ?
MLMA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rpd2lEPTB;NEGuO|U6PSEQvF2= M{niWHNCVkeHUh?=
SBC-1 NXvI[3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PMZWlEPTB;NEKuNVgxPiEQvF2= M{j4dHNCVkeHUh?=
MPP-89 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv3UolKSzVyPUSyMlU5PzVizszN NXHLcZd6W0GQR1XS
MV-4-11 Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;WTWM2OD12Mj65NFY4KM7:TR?= MX\TRW5ITVJ?
EoL-1- M{Pzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR2LkG1Olgh|ryP M2fqSnNCVkeHUh?=
CW-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTLT255UUN3ME20OE45OzR{IN88US=> NUnhTVlzW0GQR1XS
HT NYTDSoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR3LkewNFch|ryP NYriSpJ7W0GQR1XS
SW954 M1W4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3yTWM2OD12Nz60NVI5KM7:TR?= NUKyPIJPW0GQR1XS
A3-KAW Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTwVpFWUUN3ME20PU45ODZzIN88US=> NX3TZYNWW0GQR1XS
TC-YIK MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL0TWM2OD13MD6wN|Y{KM7:TR?= MVLTRW5ITVJ?
SW962 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LBN2lEPTB;NUSuPFM2PyEQvF2= M3LkOXNCVkeHUh?=
KP-N-RT-BM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO4ZoN[UUN3ME21Ok43PjN6IN88US=> MnTWV2FPT0WU
NCI-H1395 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XXZWlEPTB;NUiuPFE4OiEQvF2= M4S2W3NCVkeHUh?=
RPMI-8402 M13UVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT2bVhuUUN3ME21PE46PTJ4IN88US=> M1P4TXNCVkeHUh?=
SCH NHyyPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3LTWM2OD14MD65OlM5KM7:TR?= MkizV2FPT0WU
NCI-H2196 M4HUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTFV241UUN3ME22NU4zOzFizszN M3;qZXNCVkeHUh?=
LOXIMVI MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrzfpJUUUN3ME22NU45OjZ4IN88US=> NFnaTZlUSU6JRWK=
TGBC24TKB MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTTTWM2OD14Mj6xOFkyKM7:TR?= NIPTZ2FUSU6JRWK=
SK-MEL-2 M4\XOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnYTWM2OD14Mz65PFkzKM7:TR?= NH3jW|hUSU6JRWK=
U-698-M M{XiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHOSHpGUUN3ME22PE42Pjh5IN88US=> MUPTRW5ITVJ?
NCI-H1522 NGLWZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHKcpFKSzVyPU[5MlAxPDdizszN NIXpOXNUSU6JRWK=
UACC-812 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zh[mlEPTB;NkmuOVIxQSEQvF2= NHq4R2NUSU6JRWK=
MHH-CALL-2 NXvRUFh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WxTmlEPTB;N{CuNFYh|ryP MoHSV2FPT0WU
NB5 M1XzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTdyLkO0Olgh|ryP M3\yT3NCVkeHUh?=
KARPAS-299 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTdyLkS0OFch|ryP Ml\RV2FPT0WU
NCI-H1694 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTdzLkCzNkDPxE1? NYj0SnhOW0GQR1XS
NCI-H82 NYKzZmF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTdzLkm1NFch|ryP NW\3NXZyW0GQR1XS
SCC-15 NY\hdpZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\1TWM2OD15Mj6zOEDPxE1? M4DYcXNCVkeHUh?=
NCI-H1436 M1LxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLHdZpKSzVyPUeyMlc1PTZizszN MmfUV2FPT0WU
ATN-1 NUnlUJRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rTbGlEPTB;N{SuOVA2KM7:TR?= MWHTRW5ITVJ?
RPMI-8866 M1;wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSxTWM2OD15ND63OVA6KM7:TR?= M3vEZ3NCVkeHUh?=
HCC1599 NHm2RZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn3VIxrUUN3ME23OE45PzN{IN88US=> MVjTRW5ITVJ?
NCI-H1155 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[zWVFrUUN3ME23OE46OzZ5IN88US=> MoX3V2FPT0WU
DOHH-2 MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTd2Lkm1NVQh|ryP M2nVW3NCVkeHUh?=
SK-NEP-1 NGLHW5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTd3LkC3OVQh|ryP NV3HXFZGW0GQR1XS
HCC1187 NX;Kd49ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTd5Lk[xNlIh|ryP M4G5bHNCVkeHUh?=
NCI-H322M NFzGbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7YTWM2OD15OD6zO|A6KM7:TR?= MX\TRW5ITVJ?
NCI-H526 NUPhe2tpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTd6LkW4O|ch|ryP NELp[JZUSU6JRWK=
NCI-H2171 NWPue4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnW4TWM2OD15OT60NVM3KM7:TR?= NHq0UGlUSU6JRWK=
COLO-668 MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRThzLkW4PFQh|ryP MlGzV2FPT0WU
RS4-11 NUC4dnRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlW4TWM2OD16Mj6yOVA2KM7:TR?= NWq1ZY5PW0GQR1XS
NCI-H716 NImyNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;LUVJKSzVyPUiyMlkxPzVizszN NIS4dWhUSU6JRWK=
LU-134-A MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSyTWM2OD16Mz6xN|UyKM7:TR?= MWnTRW5ITVJ?
RPMI-8226 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPJU4FKSzVyPUi0MlIyODdizszN MmTuV2FPT0WU
KY821 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTlzLk[1OVEh|ryP NF7pRZpUSU6JRWK=
ECC4 NHfw[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTl|LkiyOlkh|ryP M3\xTHNCVkeHUh?=
EW-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDBTWM2OD17ND65NFgyKM7:TR?= NV;VOWpWW0GQR1XS
NB7 NV30c4p5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTl3Lke3PFYh|ryP NHXLSY9USU6JRWK=
NCI-H720 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{n6NmlEPTB;OUiuOFA3OSEQvF2= MlzYV2FPT0WU
NCI-H446 M{nne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLxTWM2OD17OT63OVg5KM7:TR?= MUjTRW5ITVJ?
NCI-H889 M3jBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjMTG1qUUN3ME2xNFQvOjR{IN88US=> NFfublVUSU6JRWK=
EW-22 NXezfVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3VOZlKSzVyPUGwOk4yQSEQvF2= MoG4V2FPT0WU
BV-173 NWn0doJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFyOD63Nlgh|ryP MX;TRW5ITVJ?
WSU-NHL NGLEV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnFTWM2OD1zMEmuOlcyKM7:TR?= NXjT[5R3W0GQR1XS
MN-60 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX36TJpiUUN3ME2xNFkvPjlizszN M{e3dHNCVkeHUh?=
DG-75 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{CzfGlEPTB;MUGzMlM2OiEQvF2= M2W5V3NCVkeHUh?=
DMS-79 NFHIO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK3[YtDUUN3ME2xNVcvOzh{IN88US=> Mof1V2FPT0WU
SK-MEL-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnNZYFKSzVyPUGxPE4xODlizszN NWjDPIxEW0GQR1XS
DMS-153 NIq2RnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGntZYlKSzVyPUGyNU44PDVizszN NUezWWZoW0GQR1XS
NCI-H510A MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP0TWM2OD1zMkeuN|Ih|ryP NU\QT2ZqW0GQR1XS
BE-13 NGr4XVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hx[WlEPTB;MUO0MlA1PCEQvF2= NVnkU|ZtW0GQR1XS
KP-N-YS M4DBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGxUndKSzVyPUGzPU44OzZizszN NWjMeJR[W0GQR1XS
SUP-T1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\nTWM2OD1zNEOuO|A5KM7:TR?= M3jyOnNCVkeHUh?=
EW-12 MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDCTWM2OD1zNESuOlk6KM7:TR?= MkjpV2FPT0WU
NB14 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHCd3hvUUN3ME2xOFcvODh{IN88US=> M3nvN3NCVkeHUh?=
MDA-MB-134-VI NUf0b2tLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF2OD6yOlgh|ryP MmfUV2FPT0WU
NCI-H1770 MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[0TWM2OD1zNU[uNlc6KM7:TR?= NVTVSW1oW0GQR1XS
TUR MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPxUJVzUUN3ME2xOlcvQDdizszN M3jXSXNCVkeHUh?=
NCI-H1417 NWTRU2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf6[ndKSzVyPUG4NE4{OzFizszN MXvTRW5ITVJ?
IMR-5 NUPCd5h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fjPWlEPTB;MUixMlU4OSEQvF2= Mnn2V2FPT0WU
NCI-H226 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjCSZVKSzVyPUG4PE45PjZizszN MUnTRW5ITVJ?
NCI-H187 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\PTWM2OD1zOUCuNFY1KM7:TR?= M4TWPXNCVkeHUh?=
SF539 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTF7Mj63Nlgh|ryP MWTTRW5ITVJ?
TALL-1 MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk[1TWM2OD1zOUiuN|A1KM7:TR?= MV\TRW5ITVJ?
TE-441-T NGey[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnxUplEUUN3ME2xPVkvPzN7IN88US=> MVrTRW5ITVJ?
REH M1foc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\EUZFKSzVyPUKzOk43OjZizszN NHLxW|JUSU6JRWK=
MS-1 NV;seZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7RVIZKSzVyPUKzPU4yOjFizszN M3m5ZXNCVkeHUh?=
THP-1 NHrke|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDUUGE6UUN3ME2yOlQvPzN6IN88US=> M4\0ZnNCVkeHUh?=
NCI-H1838 NYLVdmlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHYTWM2OD1{N{GuOFU3KM7:TR?= MoHwV2FPT0WU
P30-OHK NVPjWmx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlr1TWM2OD1{OEOuPFQ4KM7:TR?= NGTrWWlUSU6JRWK=
C8166 NWDRU|B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuyTWM2OD1|NEWuN|M5KM7:TR?= MlfDV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID